Credits: 0.25 AMA PRA Category 1 Credit™
 
CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-365

Overview: The chronic nature of irritable bowel syndrome (IBS) necessitates persistence when trialing treatment options. After reviewing key identifiers of IBS, we discuss a second-line treatment’s efficacy in reducing symptoms and improving quality of life for patients with continued IBS symptoms. Tune in for valuable insights to make informed recommendations for your patients.

Episode resource links:

• Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial - PubMed (nih.gov)


• https://www.aafp.org/pubs/afp/issues/2005/1215/p2501.html

Guest: Mariyan L. Montaque, DNP, FNP-BC
 
Music Credit: Richard Onorato